Risk of secondary rectal cancer and colon cancer after radiotherapy for prostate cancer: a meta-analysis
To investigate whether radiotherapy for prostate cancer increases the risk of therapy-related rectal cancer and colon cancer.
A systematic literature search was carried out using the Medline (PubMed), EMBASE, and the Cochrane Library to identify studies examining the association between radiotherapy for prostate cancer and secondary colorectal cancer (rectal cancer and colon cancer) published before March 19, 2018. The risk of second colorectal cancer after radiotherapy was summarized using unadjusted odds ratio (OR) and adjusted hazard ratio (HR) with their 95% confidence interval (CI). Subgroup and sensitivity analyses were conducted to detect potential bias and heterogeneity.
After study selection, 16 reports were retrieved for analysis. When patients received radiotherapy compared with those unexposed to radiation, there was an increased risk of the rectal cancer (OR 1.37, 95%CI 1.01 to 1.85), but not colon cancer. According to adjusted HR, there was an increased risk of the rectal cancer (HR 1.64, 95%CI 1.39 to 1.94), and colon cancer (HR 1.33, 95%CI 1.02 to 1.76). The OR for rectal cancer showed an increased risk with longer latent period (5 years lag time versus 10 years lag time, OR: 1.56 versus 2.22). Brachytherapy had no association with second cancer across all analyses.
Radiotherapy was associated with an increased risk of subsequent rectal cancer compared with patients unexposed to radiation. Colon may be free from the damage of radiation. Brachytherapy had no association with second rectal cancer or colon cancer.
KeywordsProstatic neoplasms Radiotherapy Rectal neoplasms Colonic neoplasms Neoplasms Second primary
This work was supported by the grants from National Natural Science Foundation of China (No. 81372774, No. 81572537 for Zhigang Zhao), The Key Program of Natural Science Foundation of Guangdong Province (No. 2015A030311007 for Zhigang Zhao), Yangcheng Scholar Project of Guangzhou Education Bureau (No. 12A014G for Zhigang Zhao), Science and Technology Program of Guangzhou (No. 201607010376 for Zhigang Zhao), and Science and Technology Planning Project of Guangdong Province (No.2017B030314108).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
For this type of study informed consent is not required.
- 1.Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442
- 2.Liu S, Yang L, Yuan Y, Li H, Tian J, Lu S, Wang N, Ji J (2018) Cancer incidence in Beijing, 2014. Chin J Cancer Res 30(1):13–20. https://doi.org/10.21147/j.issn.1000-9604.2018.01.02 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Hegemann NS, Schlesinger-Raab A, Ganswindt U, Horl C, Combs SE, Holzel D, Gschwend JE, Stief C, Belka C, Engel J (2017) Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis. Radiat Oncol 12(1):2. https://doi.org/10.1186/s13014-016-0738-z CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Joung JY, Lim J, Oh CM, Jung KW, Cho H, Kim SH, Seo HK, Park WS, Chung J, Lee KH, Won YJ (2015) Risk of second primary cancer among prostate cancer patients in Korea: a population-based cohort study. PLoS One 10(10):e0140693. https://doi.org/10.1371/journal.pone.0140693 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Hinnen KA, Schaapveld M, van Vulpen M, Battermann JJ, van der Poel H, van Oort IM, van Roermund JG, Monninkhof EM (2011) Prostate brachytherapy and second primary cancer risk: a competitive risk analysis. J Clin Oncol 29(34):4510–4515. https://doi.org/10.1200/jco.2011.35.0991 CrossRefPubMedGoogle Scholar
- 15.Murray L, Henry A, Hoskin P, Siebert FA, Venselaar J (2014) Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique. Radiother Oncol 110(2):213–228. https://doi.org/10.1016/j.radonc.2013.12.012 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Wallis CJ, Mahar AL, Choo R, Herschorn S, Kodama RT, Shah PS, Danjoux C, Narod SA, Nam RK (2016) Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ (Clin Res Ed) 352:i851Google Scholar
- 19.Bhojani N, Capitanio U, Suardi N, Jeldres C, Isbarn H, Shariat SF, Graefen M, Arjane P, Duclos A, Lattouf JB, Saad F, Valiquette L, Montorsi F, Perrotte P, Karakiewicz PI (2010) The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys 76(2):342–348. https://doi.org/10.1016/j.ijrobp.2009.02.011 CrossRefPubMedGoogle Scholar
- 20.Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z (2012) Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int 110(11):1696–1701. https://doi.org/10.1111/j.1464-410X.2012.11385.x CrossRefPubMedGoogle Scholar
- 21.Boorjian S, Cowan JE, Konety BR, DuChane J, Tewari A, Carroll PR, Kane CJ (2007) Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 177(3):883–887; discussion 887-888. https://doi.org/10.1016/j.juro.2006.10.071 CrossRefPubMedGoogle Scholar
- 23.Berrington DGA, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, Stovall M, Ron E (2011) Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 12(4):353–360. https://doi.org/10.1016/S1470-2045(11)70061-4
- 32.Murray LJ, Thompson CM, Lilley J, Cosgrove V, Franks K, Sebag-Montefiore D, Henry AM (2015) Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy. Phys Med Biol 60(3):1237–1257. https://doi.org/10.1088/0031-9155/60/3/1237 CrossRefPubMedGoogle Scholar
- 34.Berrington de Gonzalez A, Wong J, Kleinerman R, Kim C, Morton L, Bekelman JE (2015) Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors. Int J Radiat Oncol Biol Phys 91(2):295–302. https://doi.org/10.1016/j.ijrobp.2014.10.040 CrossRefPubMedGoogle Scholar
- 36.Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouviere O, Wiegel T, Mottet N (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642. https://doi.org/10.1016/j.eururo.2016.08.002 CrossRefPubMedGoogle Scholar
- 37.Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629. https://doi.org/10.1016/j.eururo.2016.08.003 CrossRefPubMedGoogle Scholar